JP2020514345A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514345A5
JP2020514345A5 JP2019549449A JP2019549449A JP2020514345A5 JP 2020514345 A5 JP2020514345 A5 JP 2020514345A5 JP 2019549449 A JP2019549449 A JP 2019549449A JP 2019549449 A JP2019549449 A JP 2019549449A JP 2020514345 A5 JP2020514345 A5 JP 2020514345A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
composition according
sdf
fpkm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019549449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514345A (ja
Filing date
Publication date
Priority claimed from GBGB1703907.4A external-priority patent/GB201703907D0/en
Application filed filed Critical
Publication of JP2020514345A publication Critical patent/JP2020514345A/ja
Publication of JP2020514345A5 publication Critical patent/JP2020514345A5/ja
Pending legal-status Critical Current

Links

JP2019549449A 2017-03-10 2018-03-09 新規な癌の治療法 Pending JP2020514345A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1703907.4 2017-03-10
GBGB1703907.4A GB201703907D0 (en) 2017-03-10 2017-03-10 Novel therapies for cancer
PCT/GB2018/050608 WO2018162924A1 (en) 2017-03-10 2018-03-09 Usl-311 for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2020514345A JP2020514345A (ja) 2020-05-21
JP2020514345A5 true JP2020514345A5 (cg-RX-API-DMAC7.html) 2021-04-22

Family

ID=58605592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549449A Pending JP2020514345A (ja) 2017-03-10 2018-03-09 新規な癌の治療法

Country Status (14)

Country Link
US (1) US20200281937A1 (cg-RX-API-DMAC7.html)
EP (1) EP3592356A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020514345A (cg-RX-API-DMAC7.html)
KR (1) KR20190128660A (cg-RX-API-DMAC7.html)
CN (1) CN110520130A (cg-RX-API-DMAC7.html)
AU (1) AU2018231664A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019018482A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055470A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992130A1 (cg-RX-API-DMAC7.html)
GB (1) GB201703907D0 (cg-RX-API-DMAC7.html)
IL (1) IL269121A (cg-RX-API-DMAC7.html)
MX (1) MX2019010679A (cg-RX-API-DMAC7.html)
SG (1) SG11201908166UA (cg-RX-API-DMAC7.html)
WO (1) WO2018162924A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
CN112569242A (zh) 2015-04-02 2021-03-30 普罗克斯马根有限责任公司 用于癌症的新治疗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
JP2016527303A (ja) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるcxcr4シグナル伝達の阻害
CN112569242A (zh) * 2015-04-02 2021-03-30 普罗克斯马根有限责任公司 用于癌症的新治疗
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy

Similar Documents

Publication Publication Date Title
JP2017516775A5 (cg-RX-API-DMAC7.html)
JP2016533366A5 (cg-RX-API-DMAC7.html)
JP2020502157A5 (cg-RX-API-DMAC7.html)
JP2016528162A5 (cg-RX-API-DMAC7.html)
JP2020523354A5 (cg-RX-API-DMAC7.html)
TR201807411T4 (tr) DNA-PK inhibitörleri.
JP2014525454A5 (cg-RX-API-DMAC7.html)
JP2017516775A (ja) がんの処置のための併用治療
JP2016041733A5 (cg-RX-API-DMAC7.html)
JP2016536286A5 (cg-RX-API-DMAC7.html)
JP2016519107A5 (cg-RX-API-DMAC7.html)
JP2015520753A5 (cg-RX-API-DMAC7.html)
Cho et al. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
JP2021501145A5 (cg-RX-API-DMAC7.html)
ME02470B (me) Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom
JP2019532047A5 (cg-RX-API-DMAC7.html)
JP2017530983A5 (cg-RX-API-DMAC7.html)
RU2016110874A (ru) Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний
CY1123346T1 (el) Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα
CN110678452A (zh) 亚精胺及其衍生物的应用
JP2015502926A5 (cg-RX-API-DMAC7.html)
JP2014523398A5 (cg-RX-API-DMAC7.html)
JP2008514577A5 (cg-RX-API-DMAC7.html)
JP2018062523A5 (cg-RX-API-DMAC7.html)
JP2020514345A5 (cg-RX-API-DMAC7.html)